Junshi Biosciences has become the first Chinese biopharmaceutical company to float shares on both the mainland and Hong Kong stock exchanges, after the company raised nearly 4.84 billion yuan ($692 million) in an initial public offering (IPO) on Shanghai’s Nasdaq-style STAR Market on Wednesday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
